Ulipristal acetate CAS 126784-99-4Â

Ulipristal acetate CAS 126784-99-4 

Ulipristal acetate

Synonym: EllaOne, Ulipristal ace CAS: 126784-99-4 M.F.: C28H35NO3 M.W.: 433.5824 Appearance: White crystalline powder Usage: contraceptive medicine anabolic powder Storage: Kept Ulipristal acetate in a cool, dry and ventilated place We guarantee good quality products. 100% refunded if parcel is not delivered or poor quality.

Specification: Product name: Ulipristal acetate Other Name HRP2000;(11b)-17-(Acetyloxy)-11-[4-(dimethylamino)phenyl]-19-norpregna-4,9-diene-3,20-dione;CBD 2914;VA 2914;Ulipristal;Ulipristal acetate;Ulipristal acetate/CDB2914;17alpha-Acetoxy-11beta-(4-dimethylaminophenyl)-19-norpregna-4,9-dien-3,20-dione Original China CAS 126784-99-4 Molecular formula C28H35NO3 Molecular Weight 433.5824 Brand name NJBNSteroid Delivery time within 24 hours upon receipt of payment Delivery Fast and secure shipping by EMS, DHL, TNT, FedEx, UPS Purity 99% Package Discreet and Hidden package according to specific requirement Appearance White powder Certification SGS, ISO 9001, KOSHER Payment Terms Western Union, Money Gram , T/T, Bitcoin Minimum Order Quantity 10g Price Negotiable Usage Ulipristal acetate is a selective progesterone receptor modulator MF

Description Ulipristal acetate (trade name EllaOne in the European Union, Ella in the U.S. for contraception, and Esmya for uterine fibroid) is a selective progesterone receptor modulator (SPRM).

Medical Uses Emergency contraception: For emergency contraceptiona 30 mg tablet is used within 120 hours (5 days) after an unprotected intercourse or contraceptive failure. It has been shown to prevent about 62–85% of expected pregnancies, and prevents more pregnancies than emergency contraception with levonorgestrel.

Ulipristal acetate is available by prescription for emergency contraception in over 50 countries, with access through pharmacists without a prescription being tested in the United Kingdom. From July 2016 available without prescription in Israel.

Treatment of uterine fibroids Ulipristal acetate is used for pre-operative treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age in a daily dose of a 5 mg tablet.

Treatment of uterine fibroids with ulipristal acetate for 13 weeks effectively controlled excessive bleeding due to uterine fibroids and reduced the size of the fibroids.

Two intermittent 3-months treatment courses of ulipristal acetate 10 mg resulted in amenorrhea at the end of the first treatment course in 79.5%, at the end of the second course in 88.5% of subjects. Mean myoma volume reduction observed during the first treatment course (−41.9%) was maintained during the second one (−43.7%).

After two to four 3-months courses of treatment, UPA-treated fibroids shown about -70% in volume reduction. This phenomenon was temptatively explained by the combination of multifactorial events involving control of proliferation of the tumor cells, induction of apoptosis and remodeling of the extracellular matrix.